|1.||Reddy, Doodipala S: 5 articles (05/2010 - 01/2002)|
|2.||Rogawski, Michael A: 4 articles (05/2010 - 01/2002)|
|3.||Reddy, D S: 3 articles (09/2004 - 09/2000)|
|4.||Carter, R B: 3 articles (04/2000 - 03/2000)|
|5.||Kaminski, Rafal M: 2 articles (07/2004 - 08/2003)|
|6.||Rogawski, M A: 2 articles (12/2000 - 09/2000)|
|7.||Gasior, M: 2 articles (04/2000 - 03/2000)|
|8.||Beekman, M: 2 articles (04/2000 - 03/2000)|
|9.||Witkin, J M: 2 articles (04/2000 - 03/2000)|
|10.||Ungard, J T: 2 articles (04/2000 - 03/2000)|
01/29/2010 - "We previously demonstrated that ganaxolone is effective against pentetrazol-induced motor seizures in immature rats. "
04/27/2000 - "All three drugs dose-dependently suppressed tonic seizures and lethality induced by PTZ in kindled mice; only ganaxolone was effective against clonic seizures. "
03/01/1997 - "Ganaxolone was effective in nontoxic doses against clonic convulsions induced by s.c. "
02/01/2011 - "Ganaxolone has shown promise in a variety of seizure types. "
04/01/2012 - "We also observed that treatment with ganaxolone could rescue audiogenic seizures in Fmr1 knockout mice. "
10/01/2007 - "A pilot study of the safety, tolerability, dose range and potential efficacy of ganaxolone for the treatment of refractory epilepsy in pediatric and adolescent subjects. "
01/01/2010 - "Clinical trials with the synthetic neurosteroid analog ganaxolone in the treatment of epilepsy have been encouraging. "
10/01/2007 - "We report the results of a nonrandomized, nonblinded, open-label, dose-escalation trial of ganaxolone in pediatric subjects (5-15 years) suffering from refractory epilepsy. "
03/01/2000 - "A synthetically derived neuroactive steroid, ganaxolone (3alphahydroxy-3beta-methyl-5alpha-pregnan-20-one), is in phase-II clinical trials for epilepsy. "
10/01/2007 - "Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy."
|3.||Infantile Spasms (West Syndrome)
12/01/2000 - "Ganaxolone was safe and effective in treating this group of refractory infantile spasms patients in an open-label, add-on trial. "
12/01/2000 - "Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial."
11/01/2014 - "A potential effect of ganaxolone in an animal model of infantile spasms."
10/01/2002 - "Ganaxolone, a novel neuroactive steroid has, however, demonstrated outstanding efficacy and better tolerability in children with intractable infantile spasms. "
12/01/2000 - "This is a multicenter, open-label, add-on trial, investigating the safety and efficacy of ganaxolone (GNX) in a population of children with refractory infantile spasms, or with continuing seizures after a prior history of infantile spasms. "
|4.||Absence Epilepsy (Absence Seizure)
10/01/1998 - "The object of these experiments was to ascertain the efficacy of ganaxolone against absence seizures. "
10/01/1998 - "Ganaxolone pretreatment resulted in a significant prolongation of absence seizure in both the PTZ and GHB models. "
03/01/1997 - "The profile of anticonvulsant activity obtained for ganaxolone supports clinical evaluation of this drug as an antiepileptic therapy with potential utility in the treatment of generalized absence seizures as well as simple and complex partial seizures."
10/01/1998 - "Ganaxolone was assessed in the low-dose pentylenetetrazol (PTZ) and the gamma-hydroxybutyric acid (GHB) model of absence seizures in rats. "
|5.||Temporal Lobe Epilepsy
|1.||GABA-A Receptors (GABA(A) Receptor)
|6.||Valproic Acid (Valproate, Semisodium)
|7.||Anticonvulsants (Antiepileptic Drugs)
|8.||gamma-Aminobutyric Acid (GABA)
|10.||Cocaine (Cocaine HCl)